Sunho Pharmaceutical

Beijing Sunho Pharmaceutical Co., Ltd. has always adhered to the corporate culture concept of "Surpassing Ourselves, Creating Development Together." Since its establishment in 2000, relying on strong R&D advantages, it has developed into a research-driven pharmaceutical enterprise integrating R&D, production, and sales with pharmaceutical R&D as the main focus. In August 2007, the company successfully listed on the Zhongguancun Third Board of the Shenzhen Stock Exchange, with the stock code 430017. The company now has total assets of approximately 1 billion yuan and more than 700 employees. Since its inception, the company has been committed to drug R&D, led by technological innovation, striving tirelessly to achieve the corporate vision of becoming an excellent international high-end pharmaceutical formulation service provider.In 2017, Sunho Pharmaceutical collaborated with the Chinese Academy of Sciences to establish the Beijing Center of the Chinese Academy of Sciences Drug Innovation Research Institute. In 2018, it will also establish the South China Center of the Chinese Academy of Sciences Drug Innovation Research Institute, providing CMC, CRO, and CMO services covering the entire value chain of drug innovation R&D. Currently under construction is the second production base in Beijing, with an investment of approximately 700 million yuan, integrating formulation production lines and new drug innovation incubation. The production lines meet EU and US FDA standards, and the products will be exported to Europe, America, and other regions.Sunho Pharmaceutical has been rated as a high-tech enterprise for many consecutive years, a key high-tech enterprise under the National Torch Program, and has received more than 10 honorary titles such as the National Technology Innovation Guidance Project. More than 20 projects have received national-level, provincial, and municipal funding from sources like the National Ministry of Science and Technology Innovation Fund.Sunho Pharmaceutical currently has nine production lines that comply with GMP requirements. The freeze-dried and small-volume injection workshops of its wholly-owned subsidiary, Guangdong Sunho Pharmaceutical Co., Ltd., which began operations in the first phase, were among the first domestic workshops to obtain GMP certification under the 2010 version. This workshop uses internationally advanced liquid nitrogen freeze-drying technology. The second phase is constructing small-volume injection, freeze-dried powder injection, and oral solid dosage production lines that comply with US FDA and EU EMA standards, covering the production of anti-tumor drugs and controlled-release formulations.